New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis

Henrik Nilsson; Jens Enevold Thaulov Andersen; B./W. Mueller; B. Mueller; B./W. Mueller

New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis

Henrik Nilsson (Inventor), Jens Enevold Thaulov Andersen (Inventor), B./W. Mueller (Inventor), B. Mueller (Inventor), B./W. Mueller (Inventor)

Research output: Patent

Abstract

Are useful to fight against tissue degenerative processes; and to treat psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica, lupus nephritis, myasthenia gravis, uveitis, refractory uveitis, vernal conjunctivitis, pemphigus vulgaris, scleroderma, multiple sclerosis and/or granuloma annulare; and/or to prevent organ transplant rejection (claimed). ADVANTAGE - (I) Provide an alternative and potentially improved treatment e.g. with a reduction in flushing and/or gastrointestinal related side effects and/or flush side effects with increased bioavailability. The gastrointestinal related side effect of (I) was tested in caco-2 cell monolayers using biological assay. The results showed that (I) caused no damage to the cell monolayers. DETAILED DESCRIPTION - Fumaric acid monoalkylesters of formula R1-O-C(O)-CH=COO-X+ (I) and their enantiomers or racemic mixtures, are new. R1 = 1-5C alkyl; and X+ = a protonated form of an amino acid. An INDEPENDENT CLAIM is also included for a pharmaceutical composition comprising (I).

Original language	English
Patent number	WO2007006307-A2
Publication status	Published - 2007
Externally published	Yes

Bibliographical note

Patent:
No.: IN200800534-P2

Patent:
No.: EP1915334-A2

Patent:
No.: US2008227847-A1

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis'. Together they form a unique fingerprint.

Cite this

Nilsson, Henrik (Inventor) ; Andersen, Jens Enevold Thaulov (Inventor) ; Mueller, B./W. (Inventor) et al. / New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis. Patent No.: WO2007006307-A2.

@misc{2ee66915c3554c83b66a779dfd4b1aa8,

title = "New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis",

abstract = "Are useful to fight against tissue degenerative processes; and to treat psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica, lupus nephritis, myasthenia gravis, uveitis, refractory uveitis, vernal conjunctivitis, pemphigus vulgaris, scleroderma, multiple sclerosis and/or granuloma annulare; and/or to prevent organ transplant rejection (claimed). ADVANTAGE - (I) Provide an alternative and potentially improved treatment e.g. with a reduction in flushing and/or gastrointestinal related side effects and/or flush side effects with increased bioavailability. The gastrointestinal related side effect of (I) was tested in caco-2 cell monolayers using biological assay. The results showed that (I) caused no damage to the cell monolayers. DETAILED DESCRIPTION - Fumaric acid monoalkylesters of formula R1-O-C(O)-CH=COO-X+ (I) and their enantiomers or racemic mixtures, are new. R1 = 1-5C alkyl; and X+ = a protonated form of an amino acid. An INDEPENDENT CLAIM is also included for a pharmaceutical composition comprising (I).",

author = "Henrik Nilsson and Andersen, {Jens Enevold Thaulov} and B./W. Mueller and B. Mueller and B./W. Mueller",

note = "Patent: No.: IN200800534-P2 Patent: No.: EP1915334-A2 Patent: No.: US2008227847-A1 ; WO2007006307-A2",

year = "2007",

language = "English",

type = "Patent",

}

New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis. / Nilsson, Henrik (Inventor); Andersen, Jens Enevold Thaulov (Inventor); Mueller, B./W. (Inventor) et al.
Patent No.: WO2007006307-A2.

Research output: Patent

TY - PAT

T1 - New fumaric acid monoalkylesters, useful to treat e.g. psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica and lupus nephritis

AU - Nilsson, Henrik

AU - Andersen, Jens Enevold Thaulov

AU - Mueller, B./W.

AU - Mueller, B.

AU - Mueller, B./W.

N1 - Patent: No.: IN200800534-P2 Patent: No.: EP1915334-A2 Patent: No.: US2008227847-A1

PY - 2007

Y1 - 2007

N2 - Are useful to fight against tissue degenerative processes; and to treat psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica, lupus nephritis, myasthenia gravis, uveitis, refractory uveitis, vernal conjunctivitis, pemphigus vulgaris, scleroderma, multiple sclerosis and/or granuloma annulare; and/or to prevent organ transplant rejection (claimed). ADVANTAGE - (I) Provide an alternative and potentially improved treatment e.g. with a reduction in flushing and/or gastrointestinal related side effects and/or flush side effects with increased bioavailability. The gastrointestinal related side effect of (I) was tested in caco-2 cell monolayers using biological assay. The results showed that (I) caused no damage to the cell monolayers. DETAILED DESCRIPTION - Fumaric acid monoalkylesters of formula R1-O-C(O)-CH=COO-X+ (I) and their enantiomers or racemic mixtures, are new. R1 = 1-5C alkyl; and X+ = a protonated form of an amino acid. An INDEPENDENT CLAIM is also included for a pharmaceutical composition comprising (I).

AB - Are useful to fight against tissue degenerative processes; and to treat psoriasis, psoriatic arthritis, neurodermatitis, atopic dermatitis, inflammatory bowel disease, autoimmune diseases, pain, sarcoidosis, necrobiosis lipoidica, lupus nephritis, myasthenia gravis, uveitis, refractory uveitis, vernal conjunctivitis, pemphigus vulgaris, scleroderma, multiple sclerosis and/or granuloma annulare; and/or to prevent organ transplant rejection (claimed). ADVANTAGE - (I) Provide an alternative and potentially improved treatment e.g. with a reduction in flushing and/or gastrointestinal related side effects and/or flush side effects with increased bioavailability. The gastrointestinal related side effect of (I) was tested in caco-2 cell monolayers using biological assay. The results showed that (I) caused no damage to the cell monolayers. DETAILED DESCRIPTION - Fumaric acid monoalkylesters of formula R1-O-C(O)-CH=COO-X+ (I) and their enantiomers or racemic mixtures, are new. R1 = 1-5C alkyl; and X+ = a protonated form of an amino acid. An INDEPENDENT CLAIM is also included for a pharmaceutical composition comprising (I).

M3 - Patent

M1 - WO2007006307-A2

ER -